Price movement over the last 24 hours
Arm Holdings plc vs Revvity Inc — how do they compare? Arm Holdings plc trades at $314.99 (market cap $345.41B), while Revvity Inc trades at $111.77 (market cap $12.53B). The key difference: Arm Holdings plc is far larger — about 27.6× Revvity Inc's market cap, and Revvity Inc pays a 0.25% dividend while Arm Holdings plc pays none. Which is the better fit depends on your goals.
| ARM | RVTY | |
|---|---|---|
Market Cap | $345.41B | $12.53B |
Sector | Technology | Technology |
52-Week High | $439.46 | $117.75 |
52-Week Low | $104.55 | $82.26 |
Enterprise Value | $342.26B | $15.02B |
Dividend Yield | — | 0.25% |
Signals from Pluang's Aura AI — not financial advice
ARM Holdings trades at $323.39, down 1.37% over 24 hours, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $4.01B in 2025, with net income of $792M, though valuation ratios like P/E of 380.46 reflect premium pricing. Recent news highlights ARM's role in AI infrastructure and data center expansion, driving investor optimism.
Outlook remains positive with analyst consensus favoring buy ratings (74.07%) and a $321.65 price target, but risks include high valuation sensitivity and competitive pressures in the semiconductor space. Upside potential hinges on continued AI-driven demand and execution of growth initiatives like the AGI CPU launch.
Revvity (RVTY) trades at $112.29, down 0.58% on the day, with strong technical momentum showing bullish moving averages and key support at $110. The company demonstrates consistent earnings beats with Q1 2026 EPS of $1.06 exceeding expectations, maintaining solid profitability with 54.32% gross margins. Recent developments include AI integration partnerships with Anthropic and FDA clearance for new diagnostic tests, signaling innovation in life sciences.
RVTY presents a mixed outlook with analyst consensus leaning bullish (52% buy ratings) but trading above the $109.38 price target. While strong operational cash flow ($583M in 2025) and AI expansion provide upside potential, elevated P/E ratio (53.99) and declining net cash flow (-$243M in 2025) warrant caution amid competitive pressures in healthcare technology.
Trailing returns across standard periods
Latest headlines on both assets
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →